FDA’s Shocking U-Turn on Alzheimer’s Therapy

Close-up of MRI brain scans displayed on a screen

Alzheimer’s drugs clear deadly brain plaques but fail to halt memory loss, exposing a half-century scientific chase that drained billions without delivering a cure.

Story Snapshot

Anti-amyloid drugs like aducanumab removed plaques in trials since 1999, yet cognition stayed unchanged in 2008 autopsies.
FDA approved aducanumab in 2021 as first disease-modifying therapy, discontinued it by 2024 amid efficacy doubts.
Over 200 failed trials shift focus from plaques alone to early intervention and tau tangles.
Pharma invested billions; patients face $56,000 annual costs with modest benefits at best.

Alzheimer’s Origins and Plaque Hypothesis

Alois Alzheimer identified plaques and tangles in 1906. The amyloid hypothesis gained traction in the 1990s when Elan’s 1999 vaccine cleared plaques in mice. Scientists posited amyloid-beta accumulation as the primary cause. This spurred anti-amyloid monoclonal antibodies. Cholinesterase inhibitors like donepezil in 1996 targeted symptoms by boosting acetylcholine, discovered deficient in 1976. Memantine followed in 2003 for glutamate control. These eased symptoms temporarily without altering disease progression.

Key Milestones in Anti-Amyloid Trials

Biogen’s aducanumab trials built hype in 2015 with small study plaque reductions. Phase III results mixed, prompting 2019 higher-dose halt over brain swelling safety issues. FDA granted accelerated approval in 2021 despite advisory committee rejection, calling it the first therapy targeting underlying biology. Eisai and Biogen’s lecanemab earned 2023 approval with modest cognitive slowing. Roche terminated gantenerumab and crenezumab Phase III efforts. Eli Lilly pursued solanezumab in mild cases post-2012 failure.

Stakeholders Driving Drug Development

Biogen and Eisai pioneered amyloid antibodies for revenue despite controversies. FDA and NIA balanced efficacy against safety in approvals. Alzheimer’s Association recruited trial patients and tracked milestones. Professor John Hardy, amyloid discoverer in the 1980s, now urges broader focus beyond pure amyloid. Pharma wielded development power; regulators and academics enforced checks through panels and trials.

Pfizer exited neuroscience in 2018, cutting 3,000 jobs after repeated flops. Bapineuzumab and solanezumab failed in 2012; verubecestat halted in 2017 for toxicity.

Failures Reshape Research Directions

Autopsies in 2008 confirmed plaque clearance without cognitive gains. Over 200 trials by 2019 failed, eroding amyloid dominance. Late intervention proved key flaw—plaques build decades before symptoms. Current efforts prioritize tau vaccines like ACI-35 in Phase I and combination therapies targeting amyloid plus tangles. Gantenerumab’s Phase III continues. Industry claims plaque-cognition links; skeptics cite endless failures. Consensus demands early action; no cure exists yet.

Short-term, approvals spiked Biogen stock but sparked brain swelling fears and access barriers from high costs and infusions. Long-term, partial amyloid validation shifts to prevention trials since 2014.